
A number of Pharmafile.com’s most popular stories this week are surprisingly unrelated to COVID; researchers in Scotland have made a …

NICE has decided not to recommend Bristol Myers Squibb’s Zeposia (ozanimod) for the treatment of relapsing/remitting multiple sclerosis (RRMS). In …

Independent pharmaceutical group Servier and RNA activation-focused MiNA Therapeutics have entered a research partnership to identify and develop small activating …

Eli Lilly’s neutralising antibody bamlanivimab significantly reduced the risk of contracting symptomatic coronavirus among residents and staff of long-term care …

The FDA has approved ViiV’s Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in …

Xellia Pharmaceuticals, a manufacturer of specialty anti-infective treatments, has become a member of Medicines for Europe. Medicines for Europe represents …

Eligo Bioscience has entered into a research and option agreement with GlaxoSmithKline (GSK) aimed at advancing Eligobiotics for the treatment …

The University of Oxford, the Earlham Institute, and global pharmaceutical companies Biogen and Boehringer Ingelheim are partnering to investigate a …

Thousands of people in Israel have tested positive for coronavirus after receiving the Pfizer vaccine, including some who had been …

NICE has issued a final appraisal determination (FAD) recommending the use of Jyseleca (filgotinib) on the NHS in England for …

Raremark, a global healthtech company specialising in rare disease, has appointed Nicki Grundy as Chief Financial Officer. As a key …

The past week has seen promising developments in the race to find treatments for COVID-19; Jubilant and The Wistar Institute …

Researchers in Scotland have made a discovery that could reverse the damage caused by motor neurone disease (MND). University of …

NICE has approved Amryt’s rare lipid disorder drug Myalepta (metreleptin), currently the only leptin replacement therapy available, for use within …

The EU has granted AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) conditional approval as a monotherapy for the treatment of …

The Pfizer-BioNTech COVID-19 vaccine is likely to protect against the coronavirus variant found in Britain, the latest research says. The …

The MHRA has granted a Promising Innovative Medicine (PIM) Designation to Sanofi’s nirsevimab, which is being investigated a passive immunisation …

NHS clinicians in England will be able to consider a cutting-edge cancer treatment for some patients with a form of …

India’s vaccine developer Bharat Biotech has advised a number of groups to avoid taking its homegrown COVID-19 vaccine, Covaxin. According …

Novartis has announced that Cosentyx (secukinumab) 150mg is available in Scotland on the NHS, licensed for adults with active non-radiographic …